London, UK 30 March 2021 – Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumours, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of $175.5 million. All ADSs sold in the offering are being offered by Achilles. The ADSs are expected to begin trading on The Nasdaq Global Select Market on March 31, 2021 under the ticker symbol “ACHL.” In addition, Achilles has granted the underwriters a 30-day option to purchase up to an additional 1,462,500 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 6, 2021, subject to customary closing conditions.
Anne Lane, CEO, UCLB said:
“We’re delighted to see Achilles Therapeutics, make its Nasdaq debut today. This important company milestone marks the fifth IPO that we’ve seen arising from UCL’s research base, in the past four years. It’s a testament to the talented research arising from the university, and another step towards making advancements in patient care.”